Regenerative Medicines

We support companies expanding on the success of cell therapy in hematological malignancies by tackling the effects of complex degenerative conditions such as chronic liver and kidney diseases, and developing engineered macrophages and regulatory T cells that may reverse the immune drivers of disease.